NCT05323760 is a NA clinical trial of Cardiopulmonary exercise test (CPET) in COVID-19, sponsored by Rambam Health Care Campus.

Who is sponsoring NCT05323760?

NCT05323760 is sponsored by Rambam Health Care Campus.

What drugs are being tested in NCT05323760?

Interventions in NCT05323760: Cardiopulmonary exercise test (CPET).

Is NCT05323760 still recruiting?

NCT05323760 is currently status unknown. Last updated 12 April 2022.

Last reviewed 2022-04-12 · How we verify

NCT05323760

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Functional Capacity in Patients Post Mild COVID-19

Status unknown NA Last updated 12 April 2022

What this trial tests

NA trial testing Cardiopulmonary exercise test (CPET) in COVID-19 in 100 participants. Status unknown.

Timeline

9 September 2020

Primary endpoint
31 December 2022

31 December 2023

Quick facts

Lead sponsor	Rambam Health Care Campus
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	9 September 2020
Primary completion	31 December 2022
Estimated completion	31 December 2023
Sites	1 location across Israel

Drugs / interventions tested

Cardiopulmonary exercise test (CPET)

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Rambam Health Care Campus — full company profile →

Who can join

Adults 18 to 80, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients recovered from mild coronavirus 2019 (COVID-19) disease without pulmonary involvement may experience long-term physical impairment and dyspnea. The investigators aim to characterize physiologic limitations in patients who recovered from mild COVID-19. Methods: Pulmonary function tests (PFTs), 6-minute walk test (6MWT), echocardiography and cardiopulmonary exercise test (CPET) will be completed in patients recovered from mild COVID-19 disease with prolonged dyspnea (Subgroup "A") and compared to patients recovered from moderate/severe COVID-19 (subgroup "B") and to non-COVID-19 patients with unexplained dyspnea (subgroup "C").

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Functional Capacity in Patients Who Recovered from Mild COVID-19 with Exertional Dyspnea.
Dotan Y, Weiner E, Zucker-Toledano M, Solomonov A, et al · · 2022 · cited 3× · PMID 35743659 · DOI 10.3390/jpm12060874

Verify or expand the search:

Other trials of Cardiopulmonary exercise test (CPET)

Trials testing the same drug.

NCT06796530 — High Intensity Exercise in Children With MCADD · NA · completed
NCT05205642 — Exercise Fatigue Parameters and Endothelial Function in Pediatric Patients With a History of COVID-19 Infection or MIS-C · NA · unknown
NCT04195061 — Relative Sarcopenia and Cardiometabolic Risk in Young Adults With Obesity · completed
NCT05296499 — EXERT: Exercise Physiology After Thrombosis · unknown
NCT04312802 — Cardiopulmonary Testing for Potential Pancreas Transplant Candidates · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Rambam Health Care Campus trials

Trials by the same sponsor.

NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05323760 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05323760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing